207277-66-5

207277-66-5 structure

Name	NNC45-0781
Synonyms	NNC-45-0781 YV9183IAY4 (3S,4R)-3-Phenyl-4-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}-7-chromanol 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-phenyl-4-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (3S,4R)-

Description	NNC45-0781 is a tissue-selective estrogen partial-agonist.
Related Catalog	Signaling Pathways >> Others >> Estrogen Receptor/ERR Research Areas >> Metabolic Disease
Target	Estrogen Receptor[1]
In Vivo	NNC45-0781 (NNC 45-0781) shows that it is a very promising tissue-selective estrogen agonist. Total serum cholesterol is significantly increased in the vehicle-treated group as compared to the sham animals. All of the animals receiving NNC45-0781 at doses of 10 nmol/g or higher, has significantly lower levels of total serum cholesterol as compared to the vehicle treated group[1].
Animal Admin	Rats[1] Female Sprague-Dawley rats, 12 weeks of age, weighing approximately 250 g are used in these studies.The pharmacological properties of NNC45-0781 (NNC 45-0781) are studied through a series of in vivo experiments. Activity of orally administered NNC45-0781 (1,10, 50 and 100 nmol/g) on total serum cholesterol in the ovariectomized rat.
References	[1]. Bury PS, et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002 Jan;10(1):125-45.